PRL2 inhibition, therefore, provides a mechanism and potential therapeutic strategy to elevate the level of PTEN protein, attenuate hyperactivated AKT signaling, and rescue the AML phenotype. This evidence concerns the gene AKT1 and acute myeloid leukemia.